Please login to the form below

Not currently logged in
Email:
Password:

Roche sues Dr Reddy's over Boniva for osteoporosis

Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of osteoporosis drug Boniva

Swiss-based pharmaceutical company Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of Roche's osteoporosis drug Boniva (ibandronate).

The complaint was filed on 20 September in a New Jersey court. Roche says that Boniva is covered by patents running from 2012 to 2023.

In a statement, Roche said: "This action arises because of Dr Reddy's efforts to gain approval from the FDA to market a generic copy of Roche's Boniva once-monthly drug product prior to the expiration of Roche's patent rights covering it."

Earlier in September, Roche initiated legal action against Israel-headquartered generics giant Teva Pharmaceutical's move to enter the US market with a Boniva copy.

Boniva, which is sold under the name of Bonviva in the EU, racked up sales of CHF 488m in FY06.

25th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics